259 related articles for article (PubMed ID: 12771913)
1. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
[TBL] [Abstract][Full Text] [Related]
2. Acute heart failure after treatment with 5-fluorouracil.
Georgieva S; Kinova E; Iordanov V; Gudev A; Tzekova V; Velikova M
J BUON; 2007; 12(1):113-6. PubMed ID: 17436411
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
5. [Angina attack caused by 5-fluorouracil infusion--report of a case and review of the literature].
Yokoyama T; Hosoya Y; Aoki T; Saito S; Nihei Y; Kobayashi N; Shoji M; Saito Y; Nagai H
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1805-8. PubMed ID: 12402434
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
7. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
9. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
10. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
Shaib W; Lee V; Saif MW
In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
[TBL] [Abstract][Full Text] [Related]
11. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
12. [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
Maurer U; Härle M; Jungius KP
Strahlenther Onkol; 1996 May; 172(5):257-9. PubMed ID: 8633257
[TBL] [Abstract][Full Text] [Related]
13. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
[TBL] [Abstract][Full Text] [Related]
14. [Coronary artery stenting in the treatment of 5-fluorouracil-induced unstable angina].
Grześk G; Orzałkiewicz Z; Polak G; Przybył R; Nartowicz E; Szadujkis-Szadurski L; Grabczewska Z
Przegl Lek; 2003; 60(1):46-8. PubMed ID: 12884648
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of 5-fluorouracil].
Pan L; Yang X; Song H
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.
Tsibiribi P; Descotes J; Lombard-Bohas C; Barel C; Bui-Xuan B; Belkhiria M; Tabib A; Timour Q
Bull Cancer; 2006 Mar; 93(3):E27-30. PubMed ID: 16567310
[TBL] [Abstract][Full Text] [Related]
18. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
